Skip Navigation Links.


The Translational Liver Cancer (TLC) Consortium is an NCI-funded consortium founded to advance translational research focused on early detection of liver cancer. Under the direction of the Consortium Steering Committee, the DMCC will:

  1. perform network coordination and promote collaborations among scientific investigators by providing support for Consortium meetings, developing and maintaining Consortium secure websites and listservs, and producing and maintaining all Consortium documents;
  2. support Consortium collaborative studies by working with Consortium investigators on study design, protocol development, data forms, and study manuals; coordinating and monitoring studies; tracking specimen sharing, blinding, and randomization; and performing QA/QC and study evaluation;
  3. develop and maintain a Consortium integrated information management system that provides online, end-to-end data management solutions, including study communications, regulatory compliance, remote patient registration, clinical data capture, biospecimen sample management, imaging data repository, document management, and informatic tools; and
  4. use the phased biomarker development guidelines and PRoBE study design standards to help the Consortium develop a roadmap and strategies and ensure rigor and efficiency of the Consortium collaborative phase-2 and phase-3 studies using existing and newly collected specimens from heterogeneous cohorts.